CRO Clinilabs has been selected to conduct a clinical research study on the effects of an investigational medication on the sleep of healthy volunteers.
This study uses an experimental model to assess the effects of an investigational medication on nighttime sleep and morning alertness in healthy volunteers. President and CEO Dr. Gary Zammit said the use of experimental models and biomarkers are increasingly important in early-phase drug development.
“The current study employs an experimental model of disturbed sleep that can be used as an assay to assess the potential therapeutic effects that drugs will have in patients with sleep disorders,” said Dr. Zammit. “The model will allow our client to determine if their drug should advance to later and more costly phases of testing.”
The use of such models is likely to become more common as drug makers seek more efficient ways to test investigational medications.
Clinilabs is currently enrolling healthy male and female volunteers between the ages of 21 and 65 years who are not sleep deprived and who maintain a regular sleep/wake schedule.